they didn't happen to say what type of institutions did they? I'm probably ignorant here so pardon it, but would it be financial institutions or other big pharmaceutical institutions? Thanks!
Oh and Endocyte has a Jan 2015 company brief up on their website. Maybe they are presenting at JP Morgan after all. :)
So, in case you didn't notice, the whole bio sector was down. Why is this stock down? It's trading with the sector. Unless there is momentum behind a stock it was down. Look at SGEN - and they have a credible drug. MACK has had serious support and ended down. RNN was up but there is some good news supporting it. I own MACK, ECYT, & RNN. It was just a rough week is all. Pretty volatile across the markets over all. I was pretty discouraged with RNN and if you look at the chart it has bled for quite a few months. I think there is progress there. I believe this is how ECYT is. Just slow and ugly until good news comes. Uglier if we get bad. Hoping for the best!!!
Yep, you are right. I see their logo there. I wonder why they haven't pushed out a release? Maybe they are taking a quiet approach to everything in hopes of surprising us all.
Also, all the haters out there, let's face it. This stock is boring right now. It trades between 6.10 to 6.50, always goes down on Tuesday and recovers by Friday on less than 300k shares per day. All one can do is hope that at the next CC positive news come out about them maybe moving to Cohort 5. That would be big positive IMO. Maybe I'm wrong.
Yeah, but I think it was a fluke. Was about 10k shares traded late. Hoping this year is better. Would love to hear that we are getting to cohort 5 with 1456. Any ideas on what that would mean for the share price?
There is also a 32 page slide presentation that is marked November 2014. I'm not sure if this was a CC presentation or if it was from today's event. it was good to see all the facts from the earnings CC in one place. Looks like 78% of the NSCLC data is in. Correct me if I'm wrong but the longer it takes to get this data the better. That usually means the people are still alive I would think.
Thank you for the info. I bought some of MACK but with what you're saying I think I'll try and get a buck or two out of it and move on. I agree with you in the sense that small bio rally is going on right now. At the same time, the whole market has had a late year rally. I think bio's are actually lagging considering the rest of the market. I'll look into AVAV a little more. Looks interesting.
Finally, what'd you think of ECYT's last CC? I though it interesting that the lowest dosage of 1456 has stabilized the disease and that they are in cohort 4. What are your thoughts if they make it through 4 and into 5? I always appreciate you're pragmatic input. :)
I don't think they will pursue 145 unless they get a partner. They have to manage their money closely now since they don't have one. With the cash burn and the way the market is beating this stock up and keeping it at cash value, I think the price goes down as they burn through their reserves. So they have a really dicey time ahead for them right now.
So far though, the news coming from 1456 is very good, and I can hope that value starts being assigned to it. I agree with what you are saying. Who knows maybe they will make an in road into the inflammatory realm with 1169. There is a lot of arthritis out there.
but I'm a little concerned with the light volume. Going to call it how I see it. Need a partner for 145. Need 1456 to make it to cohort 5 then on to phase 2 with good results. If either of those things happen then we'll go to the teens. In the mean time, the shorts are going to keep jerking this around. I'm long but this is how I see it unless the Bio Bull comes back around.
it kind of struck me today as to why this would trade as cash value. I noticed there has been a law suit filed but if there weren't enough people that came forward to make it worth the while then I could see a company taking on a full out attack to try and recoup their money. It could be even spite where the big money just wants to keep pulling it down to make it difficult on the company. Thoughts?
Couple things that I want to highlight here.
1. Bios are in a bear market. Look at SGEN, up almost 3 bucks last week on some good news and is almost back down to it's low. So for the bashers on this board that are saying this company sucks then need to take a macro look at everything.
2. I felt that their ability to get into the 4th cohort was pretty significant. Also was nice to hear that they expect to get the results from the NSCLC trial in the early part of next year. I took that to mean that the patient or patients are still alive which is always a good things. I want to make money like everyone else but I like to remember that people's lives are on the lines here. I would like to think that this company could maybe come up with a cure.
3. Which leads me to my third point, EC 1456 performs well against triple negative breast cancer. In fact, with that disease in mice, 1456 cured it. I was keenly interested in how they are taking different diseases and putting them in mice and treating them then developing a model off of it. I'm not sure if this is the regular practice but it sounds like a very cost efficient way to conduct analysis on your drug and how it might react in a human being.
4. I don't think we will see this stock go up for a while. it will probably trade flat for a good while till we get a positive reading somewhere.
Here are my wishes:
Partner for Vintafolide
Fast track for 1456
Oh and how about the other drugs they have in the pipeline and how they want to try treating inflammation! Something has to succeed somewhere.
It's going to take some patience and some steel stomachs, but one day we'll be rich.
Shorty in Aspen, if you read this please share your thoughts. I'm always interested in what you have to say.
Also, when you listen to the CC, these two patients were in the 1st cohort on the weakest drug dose. That holds some meaning that if at the lowest dose it stabilized the disease.
Apparently the market didn't like what was put out. The market might be in a bull phase, but I'm still convinced BIOs are a Bear.
For Endocyte, can you please get a partner for EC 145. That would help us out a TON!!!
so I hate to say it, and I've been in this stock now for over a year. This stock always goes up before earnings. It might continue after earnings then it will settle back down. For this conference call I figure that they will give guidance on how they are moving forward. After it is over, the market will price in the how much the trials they are starting are costing and we will see this thing trend back down to a level where the money spent is already factored in. I don't think we will see much upside until we here something in phase 2 that is positive or that they got a partner for EC 145. I like this company and the management team, but we have a lot more pain to feel going forward. It's rather quite depressing.
Biotechs are being taken down across the board. Look at SGEN, PCYC, and others. From a company perspective, the future of the share price is going to depend a lot on what gets put out in the quarterly earnings meeting. Then wait three more months to have the complete OS number from the NSCLC trial. I think analysts are going to be hugely critical of the decisions that the management team makes going forward. The company is at a very risky stage right now. 1456 is unknown but shows potential and 145 showed potential but is 10yrs old. What do you do in this situation? Ultimately, they need to get a drug marketed and they need to show results. From an investing standpoint, I would like to hear how they have struck a partnership for 145 again and that they will use their cash on hand to dev out 1456 and the other drugs in their pipeline that they have to shelve because they don't have the money to dev them. Just my two cents. Oh and did I say the market is horrid right now???? Common sense here folks and lots of prayers to the right business decisions being made as well as a drug approval.